Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Seres Therapeutics Inc MCRB:

• SERES THERAPEUTICS ANNOUNCES FURTHER CONSTRUCTIVE FEEDBACK FROM FDA ON SER-155 PHASE 2 STUDY PROTOCOL AND IMPLEMENTS COST REDUCTION ACTIONS TO EXTEND CASH RUNWAY

• SERES THERAPEUTICS INC - REDUCES WORKFORCE BY 25% TO EXTEND CASH RUNWAY

• SERES THERAPEUTICS INC - WORKFORCE REDUCTION TO RESULT IN $1.0-$1.4 MILLION SEVERANCE COSTS

• SERES THERAPEUTICS INC - SEEKS CAPITAL TO ADVANCE SER-155 PHASE 2 STUDY

• SERES THERAPEUTICS INC: EXPECTS TO EXTEND CASH RUNWAY WELL INTO Q2 2026